Concepedia

Elizabeth Olek

EO

14

Publications

1.2K

Citations

12

H-Index

2003

Active since

Affiliations

Loxo Oncology at Lilly (United States)(Current)

National Cancer Centre Singapore

Eli Lilly (United States)

The University of Texas MD Anderson Cancer Center

University of California, San Francisco

Elizabeth Olek is an author at Loxo Oncology at Lilly (United States) specializing in medicine, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

2003–2022

14

Publications

14

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan et al. · New England Journal of Medicine · 2020 · 810 citations · Full text

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Ezra Y. Rosen, Melissa L. Johnson, Sarah Clifford et al. · Clinical Cancer Research · 2020 · 121 citations · Full text

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

Alexander Drilon, Geoffrey R. Oxnard, Lori J. Wirth et al. · Journal of Thoracic Oncology · 2019 · 80 citations · Full text

, , +8

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Caroline E. McCoach, Christian Rolfo, Alexander Drilon et al. · Journal of Thoracic Oncology · 2022 · 54 citations · Full text

A Multicenter Study of Recombinant Human Interleukin 12 for the Treatment of Chronic Hepatitis C Virus Infection in Patients Nonresponsive to Previous Therapy

Paul J. Pockros, Keyur Patel, Christopher O’Brien et al. · Hepatology · 2003 · 40 citations · Full text

Rows per page

1–5 of 14